Sean Fetcho

If I have 5,000 Parkinson's patients that have taken our tests and we can find linkage within those patients on early stage Parkinson's that all have areas of improvement within mitochondria needed or diabetic patients or inflammation or 40-year-olds that are doing a lot of cocaine and drinking or a 50-year-old that is overweight, you want to be against the norm.

Or a professional athlete, an NFL player, NHL player, they're going to want to be against cohorts of other professional athletes to see where they are in their mitochondrial health.

So that's how we can go with this over time.

And so this data is meant for you to understand what's working for you and what's not.

And alongside of blood work, alongside of a genetic test, now you have a full picture of your overall health and wellness and where your improvement needs to be.

Beautiful.

There are others out there that are claiming that they can do some things.

There's another company out there, MitoSwab, that's been around for many, many years in the functional medicine space, and it has some utility.

It's giving you some assessment.

A lot of others claim that they're giving you assessment of mitochondria.

Mitome or MitoMe is just a white label of MitoSwab, which has been around in the industry forever.

And then there's some biomarker-based testing, epigenetic-based testing.

But look, biomarker-based testing, there's a lot of challenges there.

Okay, if you and I, after this podcast, go out, hit the bar, let's go to Phoenix Suns game.

Let's go out partying all night.

Let's hit Waffle House at five in the morning.

Let's rip some drugs at six in the morning.

Go take a biomarker-based test.

Right.

I promise you those results are going to be flawed.